However, in response to anti-VEGF therapies, some tumors can increase fibroblast growth factor (FGF) secretion, thus increasing endothelial cell proliferation, promoting tumour angiogenesis, and evading VEGF signaling inhibition. This evidence concerns the gene VEGFA and neoplasm.